Photo from wikipedia
Key Points Safety and efficacy data demonstrated that atezolizumab alone or with azacitidine did not support a favorable risk-benefit profile in MDS. The differential toxicity profile observed between patients with… Click to show full abstract
Key Points Safety and efficacy data demonstrated that atezolizumab alone or with azacitidine did not support a favorable risk-benefit profile in MDS. The differential toxicity profile observed between patients with R/R and those with HMA-naïve MDS requires additional investigation.
Keywords:
benefit profile;
favorable risk;
atezolizumab alone;
risk benefit
Journal Title: Blood Advances
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!